Prosecution Insights
Last updated: October 02, 2026

Examiner: GUSSOW, ANNE

Tech Center 2800 • Art Units: 1600 1634 1636 1642 1643 1644 1645 1671 1681 1683

This examiner grants 58% of resolved cases

Analysis

Anne Gussow serves in Tech Center 2800 and Art Unit 1600. The profile includes 349 resolved cases, which show an allowance rate of 57.9 percent. This 57.9 percent rate provides a baseline for practitioners to estimate the probability of a grant. With 349 resolved cases, the data provides a look at the examiner's tendencies in this semiconductor and biotechnology center.

The data shows an interview lift of 43.8 percent. This figure indicates that conducting an interview is associated with an increased probability of allowance compared to the baseline of cases where no interview occurs. Practitioners may consider the 43.8 percent lift when deciding whether to engage in direct communication. This positive lift suggests that verbal advocacy is a significant factor in the prosecution process for Art Unit 1600.

The median days to allowance for Gussow is 1217. This 1217-day timeline provides a benchmark for the expected duration of the prosecution process from filing to grant. The combination of the 57.9 percent allowance rate and the 43.8 percent interview lift offers a roadmap for applicants. Understanding these metrics, including the 1217-day median, helps in setting expectations for both timing and results in Tech Center 2800.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

57.9%
Allow Rate
-10.1% vs TC avg
390
Total Applications
+43.8%
Interview Lift
1217
Avg Prosecution Days
Based on 349 resolved cases, 2023–2026

Rejection Statute Breakdown

7.6%
§101 Eligibility
18.7%
§102 Novelty
28.0%
§103 Obviousness
36.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18283710 CRISPR-MEDIATED CLEAVAGE OF OLIGONUCLEOTIDE-DETECTABLE MARKER CONJUGATES FOR DETECTION OF TARGET ANALYTES Non-Final OA NORTHWESTERN UNIVERSITY
18389890 IN SITU COMBINATORIAL LABELING OF CELLULAR MOLECULES Non-Final OA UNIVERSITY OF WASHINGTON
18683969 PHARMACOGENOMICS SCORE TO MAKE DECISIONS ON THERAPY AUGMENTATION IN AML Non-Final OA University of Tennessee Research Foundation
18292884 METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS Non-Final OA Oregon Health & Science University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month